Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...

and packaging of Sanofi’s SoloStar insulin pens and advanced insulin products. This strategic partnership reinforces our ...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target ...

Analysts at Zacks Research decreased their Q4 2025 earnings estimates for Sanofi in a research note issued on Tuesday, ...

Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...

Today, there’s an immunoscience renaissance happening, and Sanofi is pushing medical research in this field forward at a much ...

Novo Nordisk May Proceed with Its Ozempic Suit Against DCA Pharmacy. A Tennessee federal court denied DCA Pharmacy’s motion ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

The global ulcerated necrobiosis lipoidica management market is poised for significant growth, with an anticipated valuation ...

Sanofi-Synthélabo is known for creating meningitis treatment, Menactra, diabetes treatment Lantus ... to continue successfully introducing new products in major markets such as the United ...